Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | KLK7 | P49862 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4798184 | 0.91 | USP2 (0.35) | USP2SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL13391280 | 0.85 | USP2 (0.36) | USP2SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL483259 | 0.76 | CHRM2 (0.43) | USP2SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL20406585 | 0.76 | CHRM2 (0.43) | USP2SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL17986859 | 0.76 | CHRM2 (0.40) | USP2SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL22990242 | 0.76 | CHRM2 (0.40) | USP2SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL13864152 | 0.76 | CHRM2 (0.40) | USP2SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL21142612 | 0.76 | CHRM2 (0.40) | USP2SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL7609856 | 0.76 | USP2 (0.35) | USP2SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL24723669 | 0.75 | CHRM2 (0.46) | USP2SMN1; SMN2CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099874-A1 | TRANSANNULAR REARRANGEMENT OF ACTIVATED LACTAMS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) | 2010-04-22 | — | — | US | disclosed |
| WO-2008125421-A1 | TRANS-ANNULAR REARRANGEMENT OF ACTIVE LACTAMES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099874-A1 | TRANSANNULAR REARRANGEMENT OF ACTIVATED LACTAMS | C9, RPS4Y1, C5 | USP2 1997/4885SMN1; SMN2 3853/4885CHRM2 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.